Moreover, endothelial CEACAM1 expression gradually declined with the advanced hepatic fibrosis stage and in parallel to the progressive increase in plasma Endothelin-1 levels of patients with MASH[76]. This evidence concerns the gene CEACAM1 and metabolic dysfunction-associated steatohepatitis.